SAB Biotherapeutics, Inc. (SABS) stock analysis

In our weekly check, SAB Biotherapeutics, Inc. is graded F (A to F). Of 21 checks on debt, profit, cash flow and trend: 6 pass, warnings: 3, red flags: 12.

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as SABS.

What our checks show for SABS

Red flags

• Operating profit does not cover the interest bill (-310x): interest is paid from cash or new debt.
• The gross margin fell by 97.3 points, to 0%: costs are rising faster than prices.
• Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
• Weak EPS forecast
• Analysts expect the net margin to shrink by 526 points from today's 0%.
• The net margin is only 0%: little room if costs rise.
• Free cash flow is negative (-4570902000% of revenue): the business spends more cash than it brings in.
• The price swings a lot: 60.6% annual volatility. Expect large ups and downs.
• The stock has fallen as much as 99% from a peak. Would you have held through that?
• The share count grew by 250% in 2 years: each shareholder owns a smaller slice.
• Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
• Pay in shares equals 0% of free cash flow: it dilutes shareholders.

Warning signs

• Earnings per share fell 6.1% a year over the last 3 years.
• A small company (market value $305 million): usually riskier and followed by fewer analysts.
• The stock is still below its previous peak.

Strengths

• Debt is low: 0.02x equity.
• The net margin rose by 28.2 points over 5 years, to 0%.
• The price is 0.9 times earnings (P/E), reasonable for its growth.
• Beta 0.58: the stock usually moves less than the market.

Next earnings report: 2026-11-05

Similar companies

BNTC · IRD · CTNM · ARCT · MPLT · SGMT

Questions

What grade does SAB Biotherapeutics, Inc. (SABS) have?

In our weekly check, SAB Biotherapeutics, Inc. is graded F (A to F). Of 21 checks on debt, profit, cash flow and trend: 6 pass, warnings: 3, red flags: 12. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of SABS stock?

This week's biggest flags for SAB Biotherapeutics, Inc.: Weak interest cover, Gross margin falling, Profits not backed by cash. In total 15 of 21 checks show a warning or a red flag.

What does SAB Biotherapeutics, Inc. do?

SAB Biotherapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as SABS.

When does SAB Biotherapeutics, Inc. report earnings next?

The next earnings report is expected on 2026-11-05. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-31

Open the full analysis